Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Start-ups
Microbiome start-up Kaleido to shut down
by Michael McCoy
April 16, 2022
| A version of this story appeared in
Volume 100, Issue 13
Kaleido Biosciences, which was developing small-molecule compounds to modulate the human microbiome, has decided to shut down. The Lexington, Massachusetts–based firm was founded quietly in 2015 and emerged in 2017 with $65 million in funding. It went public in 2019 and at the end of 2021 had 76 employees. But Kaleido disclosed in January that it had halted work on a drug in Phase 2 studies for chronic obstructive pulmonary disease and ended an agreement with the COPD Foundation.
Chemical & Engineering News
ISSN 0009-2347
Copyright © 2024 American Chemical Society
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter